Search results
Author(s):
Amarinder Bindra
,
Shelley A Hall
Added:
3 years ago
After a drought in viable new therapies for more than a decade, two new drugs for use in heart failure patients were approved by the US Food and Drug Administration (FDA) in 2015. These drugs represent two new classes of agents in the heart failure space: a combined angiotensin receptor-neprilysin inhibitor (ARNI) (sacubitril/valsartan; brand name Entresto®, Novartis) and a sinoatrial node…
View more
Author(s):
Rahul Sakhuja
,
James L Januzzi
Added:
3 years ago
Introduction
With nearly 500,000 new cases per year and direct costs estimated as high as US$38 billion annually, congestive heart failure (CHF) has become a major priority in modern medicine. This crisis will continue to grow as the population ages, thus the discernment of new diagnostic and therapeutic strategies to improve prognosis and reduce costs is critical.1
The irony is that therapies…
View more
Author(s):
Ariana Traub
,
Apoorva Sharma
,
Maria Carolina Gongora
Added:
1 month ago